Brief: Haemato Seeks Marketing Authorization And Plans Distribution Of Botulinum Toxin Product In Europe
25/10/2021 09:29
Oct 25 (Reuters) - HAEMATO AG HAEk.DE :
* SEEKS MARKETING AUTHORIZATION AND PLANS DISTRIBUTION OF A
BOTULINUM TOXIN PRODUCT UNDER ITS OWN BRAND IN EUROPE
* PARTIES HAVE AGREED NOT TO DISCLOSE DETAILED FINANCIAL
TERMS OF
AGREEMENT
* HUONS BIOPHARMA AND HAEMATO HAVE CONCLUDED AN EXCLUSIVE
LICENCE
AND SUPPLY AGREEMENT FOR PRODUCT KNOWN IN KOREA UNDER BRAND
NAMES LIZTOX(R) AND HUTOX(R)
* FOR APPROVAL IN EUROPE, BOTH SIDES ARE PLANNING A EUROPEAN
MARKETING AUTHORIZATION PROCEDURE, WHICH ALSO INCLUDES CLINICAL
TRIALS
Source text for Eikon: ID:nEQ1yFpbma
Further company coverage: HAEk.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Haemato AG
See all newsBrief: HAEMATO Raises FY EBIT Guidance to EUR 10-12 Million
Brief: Haemato Says Terminates Cooperation With Korean Manufacturer Huons Biopharma; To Discontinue Project For A Proprietary Botulinum Toxin
Brief: Haemato Q1 EBITDA At EUR 2.3 Mln
Brief: Haemato To Propose Dividend Of EUR 1.10 Per Share
Brief: Haemato Preliminary Consolidated FY EBIT Up At EUR 11.2 Mln